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Background: The medicinal plants and the associated Bhutanese traditional medicine (BTM) are protected by the
country’s constitution and receive both government support and acceptance by the wider public. More than 1000
medicinal plants are described in the BTM but currently collects only 300 species for daily formulations of BTM. These
medicinal plants have been one of the drivers of the ‘Gross National Happiness (GNH)’ and biodiscovery projects in
Bhutan. However, no review covering the systematic evaluations of the contributions of medicinal plants and the BTM
to the GNH and biodiscovery exist till date.
Methods: This paper, therefore addresses this information gap. It is based on the review of the existing traditional and
scientific literature, government websites and policy documents. The descriptions and discussions of the paper is
straightened, authenticated and enhanced by the data collected through the informal discussions with the BTM
practitioners and also through the authors’ many years of practical observations of the impact of the medicinal
plants programs and the BTM practices in Bhutan.
Results: This paper found the following: a) the medicinal plants generates income to the farmers elevating their
living standard and the economic status, b) it serves as the bulk ingredients of the BTM facilitating the provision
of free traditional health care services to the patients, c) helps the conservation of medicinal plants and their
pristine environment through recognition of their spiritual, social and economic values, d) preserves the rich BTM
cultural heritage, and e) guides the biodiscovery projects based on their ethnobotanical information. The paper
also identified the challenges and research gaps, and recommends appropriate strategies that can help secure
the sustainable future of the medicinal plants, the BTM and the biodiscovery projects.
Conclusions: The medicinal plants play significant role in the country’s biodiscovery projects and the
internationally renowned development policy of ‘Gross National Happiness’.
Keywords: Medicinal plants, Bhutanese traditional medicine, Health care services, Gross national happiness,
Biodiscovery, Environmental conservation, Socio-economic developmentBackground
The biological resources such as plants, animals and mi-
croorganisms exhibit bewildering properties wherein
their whole parts or derivatives can be used for social,
economic, environmental, traditional medicines, scien-
tific and chemotherapeutic purposes. Plants are used as
bulk ingredients in traditional medicines (TM) which
provides the primary health services to 80 % of the* Correspondence: phurpaw@yahoo.com
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unless otherwise stated.world’s population [1]. Besides playing indispensable role
in the primary health care, the medicinal plants has been
also one of the important source of modern drug discov-
eries. This is mainly because their long history of clinical
uses enhances the hit rate of a new drug lead candidate.
An analysis by Fabricant and Farnsworth [2] on the ori-
gin of the drugs developed between 1981 and 2001
showed that 80 % of 122 plant-derived drugs were re-
lated to their original ethnopharmacological uses. Be-
tween 2000 and 2005, about five medicinal plant-based
drugs were introduced in the United States market and
another seven plant-derived compounds are currently in
clinical trials around the world [3, 4].n Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wangchuk and Tobgay Journal of Ethnobiology and Ethnomedicine  (2015) 11:48 Page 2 of 12It is estimated that about 50,000 plant species are used
in the TM worldwide with majority of them being in Asian
medicines [5, 6]. These medicinal plants contain valuable
ethnobotanical information that could navigate new drug
discoveries. Table 1 shows a compiled list of the availabil-
ity of higher plants and the usage of medicinal plants by
the selected countries [5–9]. It is indicated that Indians
utilize maximum 20.0 % of their plant flora as medicinal
plants which is followed by China (18.9 %), Vietnam
(17.1 %), Sri Lanka (16.5 %) and Thailand (15.5 %). While
nations like the USA, Australia, Indonesia and Malaysia
have a high number of plant species, their utilization as
medicinal plants are low. Australia have utilized 7.8 % of
its higher plant flora as medicinal plants and this know-
ledge remains in Aboriginal communities [7].
In Bhutan, more than 5603 higher plant species are
recorded and most of them are believed to have medicinal
properties [10]. In ancient times, due to abundance of me-
dicinal plants, Bhutan was known by many synonyms as
‘bruk-tsan-dhen-b.kod-pai-rgyal-khab’ (translated as the
dragon kingdom of bountiful sandalwood) and lho-jong
sman-jong (translated as the southern land of medicinal
plants) [11]. Bhutan, which is nestled in the eastern Hima-
layas between India in the south and Tibet (China) in the
north (see Fig. 1. Map of Bhutan), is a small mountainous
country with the total area of 38,394 sq. km and a popula-
tion of 658,888, [12]. The notable differences in altitude
ranging from 150 m above sea level (masl) in the sub-
tropical south to 7500 masl in the alpine north [10], has
facilitated the development of diverse ecological zones
with rich biodiversity. With 72 % of the country still under
forest cover, it is considered as one of the ten globalTable 1 Number of plant flora and the medicinal plants
reported from selected countries [5–9]
Country Higher plant
species
Medicinal plant
species
% of medicinal
plants
Africaa 45,000 5000 11.1
Australia 19,324 1,511 7.8
China 26,092 4,941 18.9
Bhutan 5,603 600 10.7
India 15,000 3,000 20.0
Indonesia 22,500 1,000 4.4
Malaysia 15,500 1,200 7.7
Nepal 6,973 700 10.0
Pakistan 4,950 300 6.18
Philippines 8,931 850 9.5
Sri Lanka 3,314 550 16.5
Thailand 11,625 1,800 15.5
USA 21,641 2,564 11.8
Vietnam 10,500 1,800 17.1
aAll African countries combinedbiodiversity-hotspots par excellence in the world. The
economy of a country is mainly based on hydroelectricity,
tourism, mining and renewable natural resources (RNR)
including agriculture, livestock, forestry and medicinal
plants.
The impenetrable forest and ravines and the inter-
locked high mountains have secluded the inhabitant of
different valleys, which facilitated the development of
unique culture and traditions including traditional med-
ical cultures. There are two types of traditional medical
systems: an orally transmitted folklore medicines and
the scholarly g.so-ba-rig-pa medicine. While the folklore
medicines (also called the local healing practices) play
important role in the spiritual health of the communi-
ties, their use of medicinal plants are considered negli-
gible. On the other hand, the g.so-ba-rig-pa medicine
which is popularly known as the Bhutanese traditional
medicine (BTM) has been integrated with the main-
stream health care system of the country. Although,
this medical system has been adapted from the larger
corpus of scholarly Tibetan medicine, differences can
be observed in the golden needle therapy methods and
the utilization of medicinal plants in the formulations
[13]. The BTM and the Tibetan textbooks describes
more than 1000 medicinal plants and 600 of them that
grows in Bhutan have been already identified [5]. Out
of this, 300 of them are currently used on a daily basis
at the Manjong Sorig Pharmaceuticals under the Ministry
of Health in Bhutan for preparing multi-ingredient
formulations [1].
Today, the preservation of biodiversity hotspot and
rich culture and traditions including BTM forms basis
of the country’s novel development philosophy called
‘Gross National Happiness’ (GNH). The GNH was es-
poused by the fourth King of Bhutan, Jigme Singye
Wangchuck, in 1972 as a higher level development
philosophy than the conventional development princi-
ples of Gross Domestic Products (GDP) [12]. This
GNH philosophy is based on the belief that all human
beings aspire happiness and that the true development
of human society is the measure of the collective happi-
ness of people achieved through balancing spiritual
wellbeing with economic progress. The BTM and medi-
cinal plant programs play important role in improving
the wellbeing and the socio-economic status of the
people in Bhutan. The medicinal plants have empow-
ered farmers through income generation by collecting
the selected plants on an annual basis. Indeed, the me-
dicinal plant program is one of the important sustain-
able development initiatives of Bhutan. It has been
generating happiness for farmers, yak herders, brokers,
herbal industries and many stakeholders. Therefore,
this review paper describes the role of the BTM and
medicinal plant programs in achieving GNH and in
Fig. 1 Map of Bhutan [34]
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paper also identifies research gaps, and suggest per-
spectives for future research.
Methodology
The information on the medicinal plants and the BTM
were extracted from published literature and from dis-
cussions with practitioners of BTM. The published lit-
erature included scientific journals, books, reports from
national, regional and international organizations, thesis,
conference papers, policy documents, constitution, and
the related government and non-government websites.
Literature was searched on Google Scholar, SciFinder
Scholar and the PubMed Central using specific search
terms such as “Medicinal Plants”, “Bhutanese Traditional
Medicine”, “Cordyceps”, “Gross National Happiness”,
“Biodiversity”, “Biodiscovery”, “Bioprospecting”, “Integra-
tion”, Primary Health Care” and “Bhutan”. The data were
assessed and compiled. The results and discussions were
enhanced using many years of our own personal experi-
ence with the BTM and the medicinal plants collection
programs. A series of plant surveys to numerous places
and visits to two main medicinal plants collection centres,
Lingzhi (North Bhutan) and Langthel (Central Bhutan)were made during those years. The first hand field experi-
ences provided considerable enrichment of information
collected from the literature.
Results and discussions
Conceptual framework of GNH and its relationship with
the BTM and medicinal plants
The GNH-based development philosophy of Bhutan has
inspired many multinational politicians, philosophers,
scholars, economists and the United Nations (UN) due to
its holistic concept and approach to development. Profes-
sor Jeffrey D. Sachs [14], who is one of the world’s most
influential living economists and a leader in sustainable
development at the Earth Institute at Columbia University,
believes that this GNH philosophy can help recreate a
sensible economic life and happiness in America and the
rest of the world which are afflicted by rapid urbanization,
mass commercial media, global capitalism, relentless
pursuit of GDP, environmental degradation, and failing
health care system. The GNH concept is based on the
realization that collective happiness of the society is more
important than material growth alone, which has been
explained and measured by its four pillars and nine do-
mains [12]. The four pillars includes: good governance,
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ervation, and environmental conservation. The pillars
are further branched into nine domains: psychological
wellbeing, health, education, time use, cultural diversity
and resilience, good governance, community vitality,
ecological diversity and resilience, and the living stan-
dards [15]. While the BTM or g.so-ba-rig-pa medical trad-
ition falls under the pillar of preservation of culture and
traditions, its related medicinal plant programs encapsu-
lates two GNH pillars: sustainable socio-economic devel-
opment and environmental conservation (Fig. 2).
The preservation and development of the BTM and its
integration with modern medicine has broadened the
health care choices and benefited the people. While it
has huge potential to create more jobs and businesses,
the future of BTM culture and services rely on knowing
to strike a fine balance between the demand for BTM
services and the sustainable supply of medicinal plants. If
sustainable supply of medicinal plants is to be achieved,
matching the policies, good governance and the farmers’
participation to the BTM and medicinal plant programs
are essential. The existing policies and good governance
practices that favored the growth and development of
BTM is discussed in details in the section below.Fig. 2 Five pillars of medicinal plants that are contributing to GNH in BhutGood governance, BTM promotion and the creation of
employment
The good governance system established by the successive
kings, governments, and the BTM practitioners have
played significant role in the preservation and develop-
ment of this rich ethnomedical tradition and the sustain-
able utilization of the medicinal plants in the country. The
BTM and the medicinal plants are safeguarded by the
constitution and government policies. Article 9 of the con-
stitution of the Kingdom of Bhutan states that “The state
shall provide free access to basic public health services in
both modern and traditional medicines” [16]. Bhutan
2020: A Vision for Peace, Prosperity and Happiness [17]
also states that, “We must continue to provide a place for
traditional medicine in our health care system as it
embodies knowledge, draws upon the nation’s rich bio-
diversity, and provides an alternative health care choices
for those who seek one”. The national health policy of the
Ministry of Health [18] states that, “Focused efforts shall
be directed towards making the BTM, the centre of excel-
lence in providing quality traditional medical services
including wellness centre that is recognizable at an inter-
national level and that the identification, demarcation and
protection of areas rich with medicinal plants be managedan
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formity with the conservation regulations of the Ministry
of Agriculture and Forestry”.
The past governance and the developments related to
the BTM and medicinal plants in Bhutan has been de-
scribed previously [19–21]. These historical documents
highlights three important spiritual figures that have
prominently influenced and contributed to the beliefs,
faith, philosophy, inception and development of the trad-
itional medical system in the country. They are: Sangay
sman-lha (Medicine Buddha, 2500 B.C), Guru Padma
Sambhava (Tantric Buddhist saint of the 8th Century
A.D), and Zhabdrug Ngawang Namgyal (Bhutanese polit-
ical and religious leader of 17th Century A.D). The epic
transformations of BTM was ushered by the third king,
Jigme Dorji Wangchuck, who integrated the BTM with
biomedicine in 1967. The fourth king, Jigme Singye
Wangchuck, propounded the GNH philosophy in 1972
which safeguarded the BTM and ensured its continuity.
The BTM evolved from a single traditional medical dis-
pensary in 1967 to one of the complex and bigger
organization called the Institute of Traditional Medicine
Services (ITMS) in 1998. Today, there are three separate
sections responsible for the preservation, promotion and
development of BTM. The Faculty of Traditional Medi-
cine (FTM) under the Khesar Gyalpo University of Med-
ical Sciences of Bhutan (KGUMSB) offers the Drungtsho
and sman-pa courses [22]. While the term Drungtsho is
locally used for Traditional physicians after completing
5 years of degree in BTM, the term sman-pa is used for
traditional clinical assistant after obtaining three years of
diploma courses in the BTM. The Manjong Sorig Pharma-
ceuticals (MSP) conducts research and manufactures
more than 100 medicines for distributing to Traditional
Medicine Hospitals (TMH) in the country. The TMH
provides free primary health care services to the people
through 48 traditional medicine units that are estab-
lished wide across the country. Analyzing the current
organizational and human resource structure revealed
that these three organizations (FTM, MSP and TMH)
together provide employment to a total of 212 trained
people [23, 24] to cater for the traditional health care
services. In addition, many farmers, yak-herders and
business people are involved in the collection, trade
and distribution of medicinal plants. The FTM has 61
enrolled students as of 2014 [22]. As the BTM services
and related herbal industry expands, it is expected to
create more jobs in future.
Preservation of BTM through incorporation of scientific
protocols
The ITMS was given the initial mandates to preserve, pro-
mote and develop this rich traditional medical heritage.
The practitioners believed that to successfully preservethis age old tradition, the accessibility to the BTM medi-
cines and the people’s acceptance were crucial. The peo-
ple’s respect towards BTM was eminent as this medical
tradition was supposed to have originated from Gautama
Buddha’s teaching. However, as the communities became
more educated, people’s respect and acceptance relied on
scientific evidences of the BTM. Between 1980s and
1990s, numerous funding bodies including World Health
Organization, Italian DISVI project and two successive
European Union projects (Phase I in 1994–1998; Phase II
in 2006–2009) were brought in to help improve the qual-
ity of BTM and the sustainability of medicinal plants as
well as achieve long term preservation goal. Under these
projects, unprecedented progress were made in terms of
the development of the infrastructures, research and qual-
ity control protocols, manufacturing process and service
delivery system.
While modern scientific approaches including the
Good Manufacturing Practices (GMP), Good Research
Laboratory Practices (GLP), Good Collection Practices
(GCP), Good Dispensing Practices (GDP), Standard
Service Delivery and Treatment Practices (SSDTP), the
Total Quality Control System (TQCS), and the Adverse
Drug Reaction Surveillance and Reporting System
(ADRSRS) were introduced, it was made sure that the
original BTM practices were retained, preserved or
slightly adapted to current needs. For example, in the
quality control parameters of the raw materials, the
ancient/traditional methods to identify, evaluate and
grade the quality of medicinal ingredients through the
macroscopic, organoleptic property and characteristic
observation were retained and preserved. To supple-
ment these ancient quality parameters, microscopy,
physiochemical (total ash value, moisture content, loss
on drying, essential oil content) and comparative thin
layer chromatography analysis were introduced [12].
Similarly, in case of the finished products, their formu-
lations and dosages were adapted and adjusted from
the traditional dose measurement by: a) a small spoon
if it is powder, and b) traditionally prepared pills. To
make it more palatable to the patients, modern capsule
and tablet dosage forms were introduced. While the an-
cient quality parameters including observation of the
appropriate color, aroma, taste, hardness and the solu-
bility of the products were preserved; the modern test
protocols such as the measurement of pH values, fri-
ability, disintegration and bulk density, and packaging
with appropriate materials were introduced.
The laboratory quality parameters are important but the
practitioners and the MSP believed that the quality, safety,
and effectiveness of the BTM depended largely on the
quality of their raw materials and how they are handled
through collection and production processes. Therefore,
much emphasis has been given to the ancient practices of
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quality practices which has been dealt elsewhere [12]. In
terms of traditional medical service delivery, everything is
practiced as prescribed in the traditional medical texts in-
cluding the BTM’s codes of disease classification and
health problems, the standardized traditional treatment
and therapy guidelines, and the counseling of patients.
The modern GDP and ADRSRS were recently introduced
to supplement and improve the quality of the services.
The need was also felt to improve the traditional teaching
and learning methods. Recently, the FTM have incorpo-
rated the modern curriculum while preserving most of its
ancient methods including memorization and examin-
ation process.
Thus, preservation of this traditional medical heritage
can be claimed as a success. A recent study by Lhamo
and Nebel [25] on the perception and attitudes of the
Bhutanese towards the BTM health care services re-
ported that 51 % of 155 respondents of the study (only
one study area) were being treated by the BTM practi-
tioners and about 83 % of them were satisfied with its
quality and the health services. This finding suggested
that the BTM will continue to have its role as one of the
primary health care provider in the years to come.
Conservation of medicinal plants and their pristine
environment
Our review found no separate and specific act and policy
for the conservation of medicinal plants. However, the
Biodiversity Action Plan (BAP)-2009 [11] and the Health
Policy-2010 [18], provides explicit description of the
importance of the medicinal plants and their need for
protection. The environment in general is regarded as
sacred by the people because they believe local deities
reside in the pristine mountains, cliffs, riverbanks and
meadows. Even more so, the respect for the medicinal
plants and their environment are overwhelmingly higher.
The farmers regard it as a boon to have a patch of land
where medicinal plants grow abundantly. It is considered
a sin to defecate and pollute these areas and is believed
to earn good merits through collection of the medicinal
plants for the sick people. Thus, these beliefs have in-
stilled the people with the natural and ethical conserva-
tion mind-set. In addition, the income they can generate
from the cultivation and collection of medicinal plants
has strengthened their respect towards it.
The medicinal plants in Bhutan are categorized into two
types depending upon where they grow. Those medicinal
plants which grow in the alpine environment are known
as the High Altitude Medicinal Plants (HAMP) and the
other growing in the temperate and tropical environment
are called the Low Altitude Medicinal Plants (LAMP).
With the assistance from the European Union, the medi-
cinal and aromatic plants projects were implemented bythe Ministry of Agriculture by establishing a Medicinal
and Aromatic Plants Section (MAPS). This MAPS carries
out the wild medicinal plant surveys, cultivation trials, and
identifies the markets other than the MSP. The MAPS
also in collaboration with the MSP conducts farmers’
training on the sustainable collection of the wild species of
medicinal plants. To conserve the medicinal plants that
are not common, community herb gardens were estab-
lished in Lingzhi for the high altitude plants and Ling-
mithang in Eastern Bhutan for the low altitude plants.
Domestication and cultivation trials are constantly per-
formed at Yusipang in Thimphu.
Most of the HAMP grow within the protected biological
corridors and the national parks which are under the
vigilance of forest rangers. The MSP has to seek a blanket
approval for the required amount of the medicinal plants
to be collected on a yearly basis from the Department of
Forest and the concerned National Parks. The BTM
practitioners believe that the current utilization of the
medicinal plants are under sustainable range. However,
the farmers or the collectors expressed that the growth of
the medicinal plants have been shrinking in and around
the collection centres. This was due to impacts of climate
change and also as a result of the persistent collection
practices for more than 45 years. Realizing this issue, the
MSP have identified the alternative collection centres at
Tshampa in Northern Bhutan and Dagala in Western
Bhutan for HAMP, and Goshing in Southern Bhutan for
the LAMP. The risk factors for the sustainable use of
these medicinal plants in Bhutan has been discussed
elsewhere [26].
Socio-economic development through collection and sale
of medicinal plant products
Medicinal plants are the bulk ingredients used in the
multi-ingredient BTM formulations. As a result, the
medicinal plants collection program has become one of
the main income generating activities for farmers in
Bhutan (Fig. 3a). Each household are given yearly train-
ing for the sustainable collection of medicinal plants in
their localities. They are distributed with the plant list to
be collected and are paid mostly on a per kilogram wet-
weight basis. The price of the plants are fixed and revised
by the government after every two years or as and when
deemed necessary in consultation with the farmers. The
annual collections of about 116 HAMP species are carried
out in between May-August and about 92 LAMP species
in between December-February. Between 2006 and 2008,
the ITMS procured about 13 metric tons of dried medi-
cinal plants from the farmers, which in monetary terms
amounted to Nu. 4 million (USD 97,600 approximately),
and the return from the sale of these materials and their
finished herbal products amounted to Nu. 8 millions [27].
The finished herbal products manufactured and marketed
Fig. 3 a. Farmers collecting medicinal plants (courtesy: P.W collection), b. Cordyceps sinensis (Courtesy: pixgood.com)
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tion Medicines (ETPM) and 18 commercial products
including different types of health promoting herbal teas
and cordyplus products, varieties of incense and spiritual
merchandises, massage oil and mind soother balm.
The recent 2014 data was not reported in the litera-
ture but the reliable sources and the inventory list of
medicinal plants maintained by the MSP indicated
that this collection trend remained almost similar over
the last 5 years. While all the HAMP were collected
by the yak-herders from within Bhutan, more than
64 LAMP were collected by the farmers and the
remaining 28 species were supplied by the herbal sup-
pliers who generally import them from India. Our
earlier study on LAMP [13] found that as many as 16
of these imported species grow abundantly in Bhutan
and has potential to generate good income for farmers
through their cultivation and collection program. This
medicinal plant activities have had cascading effects
on many stakeholders including traditional medicine
hospitals (TMH), NITM, MSP, MAPS, farmers, semi-
nomadic yak herders, herbal markets, traders, and the
patients. If hydropower projects drives the country’s
macroeconomics, the medicinal plants programs can be
considered the microeconomics that improves farmers’
socio-economic status. Farmers have expressed that due
to the medicinal plant collection program, they could
afford good houses, horses, household amenities and
could send their children to schools. Beside medicinal
plant collection, these same farmers also earn income
by working as a porter or engaging their horses for
transporting the medicinal plants and the eco-tourists.
Thus, medicinal plant programs have brought in the
wealth, prosperity and the happiness to the farmers. It
has also improved the community dynamics, vitality
and renewed their sense of belongingness to the villagesand medicinal plants collection centres thereby prevent-
ing rural–urban migration.
One of the high value insect-fungi (Fig. 3b), which is
considered medicinal plant in Bhutan, is Cordyceps
sinensis. Marketing of Cordyceps was legalized in 2004
and has been a financial boon for many highlanders
from the districts of Bumthang, Gasa, Wangdue Pho-
drang, Trashi Yangtse, Lhuentse, Paro, and Thimphu.
For sustainability issues, every household is entitled to
three permits each costing Nu. 350 that has the validity
for a month. The assessment on the impact of this me-
dicinal plants on the livelihood of the collectors from
the selected five blocks or sub-districts of Bumthang
and Wandue Phodrang was carried out by the Ugyen
Wangchuck Institute for Conservation and Environ-
ment (UWICE) [28]. This UWICE assessment reported
that in 2012, about 394 Cordyceps collectors from the
two collection areas were involved and that they earned
about Nu. 57 million (about $ 12 million) from 2004 to
2009 which translated to each household earning about
Nu. 0.14 million since they started collecting. Majority
of this income was used for purchasing food, household
items, clothing, livestock, land and vehicle; constructing
new houses or to repair old ones; and for their educa-
tion [28]. In 2013, the Highlanders together auctioned
about 685 kgs of Cordyceps, the highest quantity so far.
Wangdue farmers collected the largest amount of about
373 kgs, which fetched them more than Nu. 1.14
million a kg and the Gasa farmers collected 101 kgs to
earn Nu. 1.21 million a kg, the highest price that year
[29]. The overall Cordyceps yield decreased slightly in
2014, with 555 kgs of Cordyceps collected and sold in
the auction yard for Nu 470 million [30]. Gasa high-
landers got the best price with an auction price of Nu
1.326 million/kg (about $26,520) and the government
earned a total of Nu. 5.64 million as royalties from these
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those collectors who took part in the Cordyceps auction
yards and does not account for those who did not take
part in the auction or who sold their collections directly to
buyers.
As the herbal industries including Bio-Bhutan, incense
factories and other non-wood related small scale industries
are beginning to grow, the demand for other medicinal
plants is also expected to rise. Number of incense factories
have doubled over the years thereby increasing demand for
the medicinal plants such as Nardostachys jatamansi
(Pang-poe), Aquillaria malaccensis (Agaru), Carthamus
tinctorus (Gur-gum), Juniperus species (Shug-pa), Canar-
ium strictum (spoe-d.kar), Saussurea lappa (Ru-rta), Inula
racemosa (Ma-nu), Pterocarpus santalinus (Tsan-den
d.mar-po) and Rhodendron species (Balu and Sulu). In
addition, many medicinal plants have huge potential for
the international market including the pharmaceuticals
and cosmetic industries. However, Bhutan must be careful
about mass commercialization of medicinal plants as it can
have irreversible negative effects on the resilience and vital-
ity of the plant species, and its environment. Lessons can
be learnt from Nepal, India and Tibet (China) where the
wild medicinal plants are being over-farmed.Biodiscovery potential of medicinal plants and current status
The strong tradition of herbal remedies within the
BTM forms a unique opportunity for biodiscovery. The
Bhutanese flora is characterized by an outstanding bio-
diversity and a large number of endemic species, many
of which forms part of the BTM pharmacopoeia. It
would be worthwhile to explore and extract that rich
ethno-botanical information so as to aid and guide the
modern drug discovery programs in the right direction.
Most of the Bhutanese plants are not studied before,
and since some of them grow in extreme climatic con-
ditions, they may be hosting cures for diseases includ-
ing HIV/AIDS, Cancer and other infectious diseases.
Realizing the huge potential of the medicinal plants, the
MSP and the National Biodiversity Centre (NBC) have ini-
tiated sporadic biodiscovery projects in collaboration with
the international organizations. The NBC have established
the collaboration with the Quantum Pharmaceuticals Pty
Ltd in Australia and Nimura Genetic Solutions, a Japa-
nese branch in Malaysia. The MSP collaborated with
the University of Wollongong (UOW) and James Cook
University (JCU) in Australia, and the BIOTEC in
Thailand. The MSP projects, where the author is fully in-
volved, achieved two objectives: a) discovered new drug
lead compounds and b) validated the claim of the BTM
uses providing scientific basis for those studied plants.
In between 2002 and 2004, four medicinal plants: Aconi-
tum orochryseum, Corydalis calliantha, Tribulus terristrisand Ranunculus brotherusi were studied for their phyto-
chemicals and pharmacological activities [5] jointly by the
MSP, UOW (Australia) and BIOTECH in Thailand. Three
new and two known diterpenoid alkaloids were discovered
from A. orochryseum [31] and one of these alkaloids, atisi-
nium chloride was identified as the drug lead compound
against the multi-drug resistant Plasmodium falciparum
malaria [32]. Similarly, four known isoquinoline alkaloids
with antimalarial activities were isolated from C. cal-
liantha where cheilanthifoline showed best in vitro activ-
ities against the P. falciparum chloroquine and antifolate
sensitive TM4 strain with IC50 values of 0.90 μg/mL and
multi-drug resistant K1 strain with IC50 values of 1.22 μg/
mL [33]. This alkaloid was also identified as the potential
antimalarial drug lead.
In between 2010 and 2014, seven medicinal plants:
A. laciniatum, Ajania nubigena, Codonopsis bhutanica,
C. crispa, C. dubia, Meconopsis simplicifolia and Pleur-
ospermum amabile; were studied for their drug lead
compounds [34]. Employing the ethno-directed bio-
rational approach, the biological activities of the crude
extracts and the isolated compounds were first deter-
mined in vitro. Out of seven plants that were studied, the
crude extracts of the five medicinal plants showed
significant anti-malarial activities against the multi-drug
resistant P. falciparum strains, one plant showed good
cytotoxicity against the mammalian KB cells, two plants
exhibited fair anti-Trypanosoma brucei rhodesiense ac-
tivity, six plants exhibited moderate TNF-α inhibitory
activities and all of the seven plants exhibited mild anti-
microbial activity [1, 35].
Inspired by these results, six of these bioactive plant ex-
tracts were further analyzed for their phytochemicals and
biological activities which resulted in the identification of
172 phytochemicals, of which 46 compounds were isolated
as alkaloids, terpenoids, furanocoumarins and flavonoids
using ESI-MS, GC-MS, NMR, IR and the single crystal X-
ray structural analysis [34]. Out of 28 compounds that
were investigated for their biological activities, 13 exhibited
positive results and four of them: protopine, scoulerine,
simplicifolianine, and luteolin-7-O-β-D-glucopyranoside;
showed strong anti-malarial activities against multidrug re-
sistant P. falciparum strains: TM4/8.2 and K1CB1 which
were identified as new drug leads [34]. An antimalarial pa-
tent has been obtained for one of the new alkaloid, simpli-
cifolianine which was isolated from M. simplicifolia [36].
Protopine was isolated from C. crispa [37], luteolin-7-O-β-
D-glucopyranoside from A. nubigena [23] and oxypeuceda-
nin methanolate which had moderate antimalarial activity
was isolated from P. amabile [38, 39]. An alkaloid-A1
isolated from C. dubia (under investigation), showed
significant inhibition of the acetylcholinesterase with a
minimum inhibitory requirement of 0.0015 nmol (A1),
which is almost two-fold better than the galanthamine
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disease [40].
These biodiscovery studies also discovered five new
phytochemicals (Fig. 4) from three medicinal plant
species: A. orochryseum, C. dubia and M. simplicifolia.
Orochrine (1), 2-O-acetylorochrine (2) and 2-O-acetyl-
7α-hydroxyorochrine (3) were isolated from A. orochry-
seum [5]. Dubiamine (4) was isolated from C. dubia [40]
and simplicifolianine (5) from M. simplicifolia [36]. The
new compounds were named after their species as:
orochrine based on orochryseum, dubiamine based on
dubia and simplicifolianine after simlicifolia.
Overall, these studies provided the scientific evi-
dences to the ethnopharmacological uses of the Bhu-
tanese Himalayan medicinal plants and identified the
new drug lead compounds thereby demonstrating the
effective role of medical ethnobotany in the drug dis-
covery initiatives in Bhutan. The financial return from
the biodiscovery projects are not guaranteed and the
average duration for the drug development involving
clinical trials takes about 8–12 years. However, given
that the country still has 2/3 of her biodiversity intact
and that it has huge bioprospecting potential, there is
no reason why Bhutan cannot pursue properly planned
biodiscovery programs that could bring in million dol-
lar revenues if one new drug can be discovered.
Challenges of the medicinal plants, BTM and the
biodiscovery programs
The medicinal plants programs have huge socio-economic
bearing including free health care and traditional medical
education, income generation, and the preservation ofFig. 4 Structure of new phytochemicals isolated from the Bhutanese meditraditional medical heritage and environment. The
main challenge for the MSP has been securing constant
supply of medicinal plants. Whole activities depend on
the medicinal plants and any mismanagement brews
collapse of the whole fabrics of the BTM system. The
guidelines for identification and collection of medicinal
plants in Bhutan [41] states that the current utilization
of medicinal plants by the MSP is under sustainable
range. However, expansion of the traditional health care
units from the current 48 BTM units to cover all the
178 Basic Health Units (as planned by the government)
in the country, will require 4 times more medicinal
plants supplies to meet the medicine production de-
mand. This would put pressure on the medicinal plants
and their environment if proper management plans are
not laid down. The rising herbal industries including
incense manufacturers and the illegal networks of
herbal traders already adds to this problem. The domesti-
cation and cultivation trials of some of the endangered
species are yet to bear fruit. The dilemma is whether to
expand the traditional medical health care services to the
people at the expense of long term threat to the sustain-
ability of the medicinal plants and their environment. The
balancing act in these regard has been very challenging
even at the current scenario.
For BTM, the challenge stems from the manufactur-
ing aspects in terms of maintaining the quality of the
medicines. The preparation of the polyherbal formula-
tions encounters the following issues: a) some of the
ingredients are becoming rare to find and its exclusion
from the prescribed formulations could compromise
the quality of the polyherbal formulations, and b) thecinal plants
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few products have even become more expensive than
the modern allopathic drugs thereby undermining the
affordability to manufacture them by the MSP. In
addition, due to exorbitant price fetched by the Cordy-
ceps sinensis in the open market, the interest of some
of the highland yak-herders in collecting other medi-
cinal plants (sold solely to MSP by the collectors) has
been dwindling over the years. Rewiring their interest
would mean hiking the prices of the medicinal plants,
which would shoot up the production cost to even
higher level. Since some of the polyherbal formulations
contain as much as 35 ingredients, developing appro-
priate quality parameters and assessing their quality in-
cluding the identification of the marker compounds
and the biological activities becomes complex, difficult
to achieve and costly. In general, the quality, safety, and
effectiveness of the multi-ingredient formulations de-
pend on the quality of their source materials and how
they are handled through collection and the production
processes. Therefore, much impetus has been given to
first address the quality of the source materials or indi-
vidual plants that make up the more complex polyher-
bal formulations. Even doing this involves research
protocols developed for modern medicines, which often
does not suit the complexities of the BTM. Whatever
the research that has been carried out at MSP so far
has focused on surveying and authentication of medicinal
plant species, documenting folklore medicines (ethnome-
dicines), developing monograph and the product profiles,
establishing quality control parameters and daily monitor-
ing of both raw materials and finished products through
basic analytical methods, and standardization of the pro-
duction processes.
The biodiscovery initiatives under the government own-
ership have begun but has long way to go. Carrying out
good and comprehensive scientific biodiscovery research
requires adequate laboratory infrastructure, financial
resources and the multi-disciplinary approach involving
different expertise including the traditional medical practi-
tioners, ethnobotanists, pharmacognosists, phytochemists,
pharmacologists and modern doctors. Some of these has
been lacking at both the MSP and the NBC. Moreover, be-
ing a Buddhist country, there is a strong culture of respect
for animals. Conducting animal studies, which is an essen-
tial component of biodiscovery, have been not well
received by the BTM practitioners in Bhutan. It is challen-
ging to involve the Drungtshos (traditional physicians) in
research as they are the practitioners of BTM that has so
much to do with Buddhism, which requires oath taking
for not to kill but to save all forms of lives including hu-
man and animal. Thus, collaboration is the best strategy
for successful implementation of biodiscovery projects in
Bhutan.Conclusion and future directions
It is understood that the medicinal plants program is one
of the sustainable vehicles of GNH. Given that there is
good government support and dynamic governance in this
area, other pillars of medicinal plants-based GNH includ-
ing preservation of rich traditional medical culture,
conservation of medicinal plants and their environment,
sustainable socio-economic development and biodiscovery
would all fall in place. Despite numerous challenges, the
medicinal plants are seen as a golden goose for the
farmers that helps them in generating income and over-
turning their poverty. For patients, its formulations or
medicines is a solace of treatment and cure. For the BTM
practitioners, it is a source of employment. For the chem-
ist and researchers, it is a potential chemotherapeutic pool
waiting for biodiscovery. Overall, this medicinal plant
programs accelerates the community vitality, dynamics
and the well-being of the society, and produces prosperity
and the happiness. Failing to maintain the sustainable
growth and supply of medicinal plants would mean down-
fall of these whole fabrics of developments. It would nega-
tively affect the networks of medicinal plants stakeholders
including patients, farmers, brokers, business people,
buyers, MSP, TMH, FTM, MAPS and the NBC. Therefore,
it is vital to maintain, manage and utilize the medicinal
plants wisely and have proper long-term sustainable man-
agement plan.
While the current consumption of medicinal plants in
Bhutan is considered under sustainable range, there does
not exist proper research data that suggest their long-
term sustainability. Since the yak-herders and famers
have already expressed the difficulties to collect some of
the medicinal plants in required quantities by MSP,
urgent research to analyze this issue and understand the
impact of current collection practices in the existing
collection centers is quintessential. The MSP, MAPS and
the NBC have done sporadic surveys including the value
chain analysis of few plant species and LAMP surveys in
selected districts. However, there is need for conducting
more systematic medicinal plants survey covering whole
country which could facilitate the establishment of the
new alternative collection sites for MSP wherein the
farmers are the benefactors. These suggested studies and
survey findings would help the government and the
policy makers in drawing proper management plans for
the medicinal plants and also in regulating the number
of the establishment of herbal industries in the country.
Although, higher the numbers of herbal industries mean
creating more businesses and jobs, it should not come at
the cost of over farming or depleting medicinal plants
and their environment.
Biodiscovery research and quality assurance of the medi-
cinal plants has been the focus of discussions both within
the MSP and the Ministry of Health. The MSP and the
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government) to initiate the preliminary biodiscovery pro-
jects. However, division of financial resources between
these two organizations have limited the growth of
advanced research laboratory and the technically qualified
human resource development. Assimilating the efforts,
financial resources and the research facilities of those two
organizations or combining them and establishing as one
government-owned autonomous Biotechnology laboratory
would make the biodiscovery initiatives more efficient and
cost effective. There is need to expand and enhance
research collaborations especially with the regional WHO
recognized traditional medical research centers and with
other biodiscovery research organizations. Even big uni-
versities and the research institutes rely on strong collab-
orative approach, as the biodiscovery research requires
multi-disciplinary expertise and facilities that are very dif-
ficult to establish and harmonize in just one organization
owing to capital intensiveness.
However, while looking for the collaboration partners,
the most difficult process is the intellectual property rights
protection. The NBC and the Intellectual Property Rights
Division under the Ministry of Trade and Industry have
developed the acts and other legal frameworks pertinent
to the use of natural resources and biodiversity, patenting
and ownership. The recent Biodiversity Action Plan-2009
[5], which is a built up of the previous acts of 1998, 2002
and 2003; places greater emphasis on protecting farmers’
rights and guarantees equitable benefit sharing from the
use of the resources including biodiscovery from medi-
cinal plants. Bhutan is also signatory to the United Nations
Convention on Biological Diversity. Governed by these
acts, the MSP and the NBC have successfully completed
few rounds of biodiscovery collaborations with the se-
lected universities and pharmaceutical companies. For
example, the 2010–2014 (4 years duration) collaboration
coordinated by the author between the MSP and NBC in
Bhutan, UOW and JCU in Australia, and the BIOTEC in
Thailand have been successfully completed and landed
with two patent applications. Collaboration using similar
model can be implemented in Bhutan.
In summary, while the BTM and the medicinal plants
programs have significantly contributed to the growth of
economic, health and wellbeing of the people, it can be
enhanced through immediate attention to the following:
 Assessment of the impact of current harvesting
practices to the medicinal plants.
 Further surveys of medicinal plants across Bhutan,
to more thoroughly understand their distribution,
abundance and ecology.
 Develop management plans for all the wild types of
medicinal plants in order to help regulate their long
term sustainability. Enhance medicinal plants cultivation trials to
conserve uncommon species. Cultivating all the
imported LAMP within Bhutan can generate more
income to the farmers and therefore requires urgent
attention.
 Expand and enhance research collaborations to
facilitate further scientific studies and biodiscoveries.
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